PRaG-1 immune therapy for advanced cancer
Part of Cancer clinical trials.
This trial tests a new treatment called PRaG-1 that helps your immune system fight cancer. It is for people with advanced cancer who are generally healthy and do not have serious heart or immune problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that can be treated with the study drug.
- You should not have had any other cancer (except some skin cancers or early cervical cancer) in the last 5 years.
- You must not have serious heart disease, like heart failure or a recent heart attack.
- You cannot be taking immune-suppressing drugs or have a weakened immune system.
- You must not have a serious active infection or poorly controlled major organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to combine two types of radiation therapy (called PRaG-1 and PRaG) for people with advanced solid tumors that have few treatment options. The goal is to see if this approach can help your immune system fight the cancer better.
This trial tests a supplement derived from cordyceps mushrooms to see if it can raise low CD8+ immune cell levels in people who have had solid tumors. It may help strengthen your immune system after previous cancer treatments.
This trial tests an investigational drug called RP-001 in people with advanced solid tumors. It aims to see if RP-001 can help when given alone, especially in cancers that may respond to a class of chemotherapy called taxanes, or in pancreatic or colorectal cancer that has returned or not responded to prior treatment.
This trial tests an experimental drug, IMC-P115C, for people with advanced cancers that have a specific marker called PRAME and a genetic type HLA-A*02:01. It may be an option if other treatments have stopped working or caused side effects.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
This trial tests a new combination treatment (PRaG therapy) for patients with locally advanced pancreatic cancer that has not spread. It aims to help shrink the tumor so it can be removed surgically, and it is for patients who have not had prior radiation, chemotherapy, or immunotherapy.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.